CBD

FDA, FTC Send Warning Letters To Three CBD Marketers For False Medical Claims

The move comes as CBD continues to grow in popularity

The Food and Drug Administration and the Federal Trade Commission sent warning letters Tuesday to three companies that market CBD products, saying the companies are making false claims about treating diseases such as cancer and Alzheimer’s.

The agencies claim that three companies — Nutra Pure, PotNetwork Holdings, and Advanced Spine and Pain — are falsely advertising the effectiveness of supplements that contain cannabidiol, commonly known as CBD. The products are marketed under names such as “Hemp Oil,” “CBD Softgels,” “CBD for Dogs,” “Liquid Gold Gummies,” and “CBD Oil.” One company in particular — Nutra Pure — advertises that scientific research supports their claims that their CBD product is an effective anti-seizure medication.

“According to their advertisements, the products can effectively treat diseases, including cancer, Alzheimer’s disease, fibromyalgia, and ‘neuropsychiatric disorders,’” the FDA and FTC said jointly in a statement.

The letters instruct the companies to notify the FTC within 15 days of receipt of the letter of the specific action taken to address the agency’s concerns.


To Read The Rest Of This Article On NBC News, Click Here

Stay up-to-date!

Get all the news and info straight into your inbox that you need to help grow your business.

Click to comment

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

To Top